Early clinical data on zoldonrasib at AACR 2026 highlighted objective responses in previously treated KRAS G12D–mutant non-small cell lung cancer, a subgroup lacking approved RAS-directed options. In the reported recommended phase 2 dose cohort, the study evaluated safety and efficacy among patients with prior checkpoint and platinum exposure. Investigators reported a confirmed objective response rate of 52% with a disease control rate of 93%, and median progression-free survival of 11.1 months. The median duration of response was not estimable at the time of analysis, with follow-up at 13.1 months. The dataset supports ongoing expansion of the program in combination settings, including trials exploring combinations with daraxonrasib and standard-of-care regimens, with the central goal of establishing durable activity in an intensely competitive NSCLC landscape.